Document:

Exhibit 10.1

    

    

    
      
        
          Confidential

           

        

      

    

    CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.  SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH
      “[***]”.

     

    FIRST AMENDMENT TO FACTOR B DEVOLOPMENT, COLLABORATION, OPTION AND LICENSE AGREEMENT

     

    This FIRST AMENDMENT TO FACTOR B DEVELOPMENT, COLLABORATION, OPTION AND LICENSE AGREEMENT  (the “Amendment”) is entered into as of the
      8th day of July, 2022 (the “Amendment Effective Date”) by and among Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, California 92010 (“Ionis”), and F. Hoffmann-La Roche Ltd, a Swiss corporation, having its principal place of business at Grenzacherstrasse 124, 4070
      Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc., a New Jersey corporation, having its principal place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424 (“Roche US”; Roche Basel and Roche US are collectively referred to as “Roche”). Roche
      and Ionis each may be referred to herein individually as a “Party” or collectively as the “Parties.” All capitalized terms used in this Amendment but not otherwise defined herein will have the meaning set forth in the Agreement (as defined below).

     

    RECITALS

     

    WHEREAS, Ionis and Roche entered into the Factor B Development, Collaboration, Option and License
        Agreement on October 9, 2018 (the “Agreement”);

     

    WHEREAS, the Parties now wish to amend certain provisions of the Agreement as set forth herein;

     

    NOW, THEREFORE, in consideration of the foregoing and the agreements set forth herein, and for
        other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

     

    1.          ARTICLE 2 is deleted in its entirety and replaced with new ARTICLE
            2 as follows:

     

    “The intent of the Collaboration is for the Parties to develop IONIS-FB-LRx (i) for the treatment of immunoglobulin A nephropathy (“IgA Nephropathy”), and (ii) potentially
      for the treatment of geographic atrophy (“GA”).  Ionis will Develop IONIS-FB-LRx through Completion of the Proposed Phase 2 Trials.  Roche will have an Option to obtain an exclusive license to further
        Develop, Manufacture, and Commercialize IONIS-FB-LRx.  Subject to Section 6.2, the Option will be
        deemed exercised on the Amendment Effective Date.  From and after the Amendment Effective Date, Roche will be responsible for all further Development, Manufacturing and Commercializing activities related to the Products, except for the Phase
      2 GA Trial and the Phase 2 IgA Nephropathy Trial being conducted by Ionis under the Development Plan.  Ionis will remain responsible for conducting the Phase 2 GA Trial and the Phase 2 IgA Nephropathy Trial and will be responsible for the costs and
      risks associated therewith, until Completion of such Phase 2 GA Trial and the Phase 2 IgA Nephropathy Trial. The Parties will discuss in good faith and agree to the strategy and execution of the Phase 2 IgA
      Nephropathy Trial.  The purpose of this ARTICLE 2 is to provide a high-level overview of the roles, responsibilities, rights and obligations of each Party under this Agreement with regard to the Development
        and Commercialization of the Products, and therefore this ARTICLE 2 is qualified in its entirety by the more detailed provisions of this Agreement set forth below.”

     

    
      
        

      
        Confidential

      

    

    
    2.          Section 3.1.7 is added as follows:

     

    “Until the Phase 2 IgA Nephropathy Trial is Completed or terminated, Roche will reimburse Ionis [***] for the [***].”

     

    3.          Section 6.1 is deleted in its entirety and replaced with new Section 6.1 as
          follows:

     

    “Option. Ionis hereby grants Roche an exclusive option to obtain the license set forth in Section 7.1.1 (the “Option”), which Option is deemed exercised by Roche on the Amendment Effective Date.”

     

    4.          Section 6.2 is deleted in its entirety and replaced with new Section 6.2 as
          follows:

     

    “Option Exercise; Option Expiration.  If, within [***] after Roche’s receipt of an invoice from Ionis for the license fee set forth in Section 9.3
      (the “License Fee Payment Deadline”), Roche pays Ionis the license fee set forth in Section 9.3, Ionis hereby grants to Roche the license set forth in Section 7.1.1.  If by
      the License Fee Payment Deadline Roche fails to timely pay Ionis the license fee set forth in Section 9.3 and does not cure this failure within [***] after receiving notice of such failure from Ionis, then Roche’s Option will be deemed
      expired.  If Roche’s Option expires, then the Agreement shall expire and Section 13.4.1 and Section 13.4.2 will apply.”

     

    5.          Section 8.1 (the first paragraph, i.e. excluding subsections 8.1.1 through 8.1.7) is
          deleted in its entirety and replaced with new Section 8.1 as follows:

     

    “Roche Diligence.  After Option exercise, subject to the terms of this Agreement, Roche is solely responsible for all Development, Manufacturing and
      Commercialization activities, and for all costs and expenses associated therewith, with respect to the Development, Manufacture and Commercialization of the Products, except with respect to any Phase 2 Trial being conducted by Ionis under the
      Development Plan that has not yet Completed by the time of Option exercise, which will remain the responsibility of Ionis until such Phase 2 Trial has Completed; provided that the Parties will discuss in good
      faith a possible strategy that utilizes [***]. Roche will use Commercially Reasonable Efforts to Develop, Manufacture and Commercialize Products in [***], including to meet the timelines and milestones set forth in the Development Plan, the IDCP and
      the Specific Performance Milestone Events.  If IONIS-FB-LRx meets the primary efficacy endpoint in the Phase 2 GA Trial with no unexpected safety findings and [***], then
      the Parties will [***].”

     

    
      

      2

      
        

      
        Confidential

      

    

    6.          Section 8.1.3 is deleted in its entirety and replaced with new Section 8.1.3 as
          follows:

     

    “Investigator’s Brochure.  Ionis will provide updated versions of the investigator’s brochure to Roche Annually and upon any substantive change to the
      safety or risk of the Products until the Completion or termination, as applicable, of the Proposed Phase 2 Trials.  From and after the Completion or termination, as applicable, of the Proposed Phase 2 Trials, and in addition to the IDCP, Roche will
      keep Ionis reasonably informed with respect to the status, activities and progress of Development of Products by providing updated versions of the investigator’s brochure to Ionis Annually and upon any substantive change to the safety or risk of the
      Products.”

     

    7.          Section 9.3 is deleted in its entirety and replaced with new Section 9.3 as follows:

     

    “License Fee.  Pursuant to Section 6.2, within thirty (30) days after receipt by Roche of an invoice therefor from Ionis, Roche will pay to
      Ionis a license fee of [***] within the timelines set forth in Section 6.2.”

     

    8.          Section 9.4 is deleted in its entirety and replaced with new Section 9.4 as follows:

     

    “Milestone Payments for Achievement of Post-Licensing Milestone Events. As further consideration for the licenses granted herein, Roche will pay to
      Ionis the applicable one-time milestone payments set forth in Table 1 below (each, a “Post-Licensing Milestone Payment”) when the
      corresponding milestone event listed in Table 1 (each, a “Post-Licensing Milestone Event”) is first achieved by a Product for the
      specified Indication:

     

    
      	
              Table 1

            

    

    
      	 	
              Post-Licensing

              Milestone Event

            	 	
              Post-Licensing

              Milestone

              Payment – GA*

            	 	
              Post-Licensing

              Milestone

              Payment – IgA

              Nephropathy

            	 	
              Post-Licensing

              Milestone

              Payment – First

              Additional

              Indication

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            
	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            	 	
              [***]

            

    

    

    

    
      

      3

      
        

      
        Confidential

      

    

    * Post-Licensing Milestone Payments for GA in this Table 1 are payable for Post-Licensing Milestone Events with respect to GA; however,
      if [***], then Roche shall [***]. If, however, [***], then upon the [***] in GA, Roche shall pay to Ionis [***] for the [***] Post-Licensing Milestone Payment in GA, and, for clarity, in case such scenario occurs, Post-Licensing Milestone Payments
      are due only to the extent not previously paid for the second column of Table 1 (i.e. for GA).  If [***], then such Indication shall be treated as an Additional Indication and the [***]
      will be payable as set forth in Table 1 to the extent not previously paid for a [***].

    

    

    9.          Section 9.6.3 is deleted in its entirety and replaced with new Section 9.6.3 as
          follows:

     

    “If a particular Milestone Event is achieved contemporaneously with or in connection with another Milestone Event, then both Milestone Events will be deemed achieved and the milestone payments for
      both Milestone Events will be due.  If [***] for GA is achieved before [***] for IgA Nephropathy has been achieved, then both the [***] for GA and the [***] Post-Licensing Milestone Payments will be due.  If, however, [***] for IgA Nephropathy is
      achieved before [***] for GA is achieved, then the [***] Post-Licensing Milestone Payment will be due, and the [***] Post-Licensing Milestone Payment for GA will not be due until the [***] for GA is achieved.”

     

    10.        Section 13.1.3 is deleted in its entirety and replaced with new Section 13.1.3 as
          follows:

     

    “where Roche has not paid the license fee set forth in Section 9.3 by the License Fee Payment Deadline or the [***] cure period thereafter.”

     

    11.        Section 14.4.5 is deleted in its entirety and replaced with new Section 14.4.5 as
          follows:

     

    “After Option Exercise.  After Option exercise, Ionis will have the right, consistent with its practice with its other compounds and products, to issue
      press releases, publish, present or otherwise disclose the progress and results regarding the Proposed Phase 2 Trials to the public; provided, that with respect to any proposed press release or other similar
      public communication by Ionis regarding the Proposed Phase 2 Trials, (i) Ionis will submit such proposed communication to Roche for review at least ten (10) Business Days in advance of such proposed public disclosure, unless such proposed public
      disclosure is with respect to a matter for which, in the opinion of Ionis’ legal counsel, Ionis has a disclosure requirement under applicable law, regulations or rules, in which case Ionis will submit such proposed communication to Roche for review
      as soon as reasonably practicable, but in no event less than two (2) Business Days in advance of such proposed public disclosure, (ii) Roche will have the right to review and request changes to such communication, and (iii) Ionis will incorporate any
      reasonable changes that are timely requested by Roche.  With respect to all other press releases, publications, presentations or other disclosures regarding the progress and results of IONIS-FB-LRx to the public, Roche will have the sole right after Option exercise, consistent with its practice with its other compounds and products, to issue such press releases, publications, presentations or other disclosures
      regarding the progress and results of IONIS-FB-LRx; provided, that with respect to any such proposed press release or other
      similar public communication by Roche disclosing regulatory discussions, the efficacy or safety data or results related to the Products or Roche’s sales projections, (i) Roche will submit such proposed communication to Ionis for review at least two
      (2) Business Days in advance of such proposed public disclosure, (ii) Ionis will have the right to review and recommend changes to such communication, and (iii) Roche will in good faith consider any changes that are timely recommended by Ionis.”

     

    
      

      4

      
        

      
        Confidential

      

    

    

    12.        Section 15.1.1 is deleted in its entirety and replaced with new Section 15.1.1 as
          follows:

     

    “Escalation.  If any dispute occurs under this Agreement (other than a dispute regarding the construction, validity or enforcement of either Party’s
      Patents, which disputes will be resolved pursuant to Section 15.2), either Party may request in writing that the dispute be referred for resolution to the Head of Roche Partnering of Roche and the Chief Business Officer of Ionis (the “Executives”), or their delegates. Within thirty (30) days after such a request, the Executives will meet in person at a mutually acceptable time and location or by means of telephone or video
      conference to negotiate a settlement of the dispute. Each Party’s JSC representatives may participate in such meeting if desired. If the Executives fail to resolve the dispute within such thirty (30)-day period, then, except as set forth in Section

        4.1.1(b)(ii), the dispute will be referred to binding arbitration under Section 15.1.2.”

     

    13.        In Appendix 1, the definition of “Full Enrollment” is added as follows:

     

    “‘[***]’ means [***].”

     

    14.        In Appendix 1, the definition of “Option Period” is deleted in its entirety.

     

    15.        In Appendix 1, the definition of “Option Deadline” is deleted in its entirety.

     

    16.        In Appendix 1, the following definition is added:

     

    “‘License Fee Payment Deadline’ has the meaning set forth in Section 6.2.”

     

    17.        In Appendix 1, the definition of “Second Indication” is deleted in its entirety.

     

    18.        In Appendix 1, the definition of “Successful Futility Analysis” is added as follows:

     

    “‘[***]’ means [***].”

     

    
      

      5

      
        

      
        Confidential

      

    

    19.        In Appendix 1, the definition of “Additional Indication” is added as follows:

     

    “‘Additional Indication’ means (i) any Indication other than (y) GA or (z) IgA Nephropathy, or (ii) [***].”

     

    20.        In Appendix 2, [***] are deleted.

     

    21.        This Amendment and any dispute arising from the performance or breach hereof will be governed by and construed and enforced in
        accordance with the laws of the State of California, U.S., without reference to conflicts of laws principles.

     

    22.        The Parties agree that all terms of the Agreement not specifically modified by this Amendment will remain in full force and effect.

     

    23.        The Parties have agreed to Ionis issuing the press release attached to this Amendment.

     

    24.        This Amendment may be signed in counterparts, each and every one of which will be deemed an original, notwithstanding variations in
        format or file designation that may result from the electronic transmission, storage and printing of copies from separate computers or printers.  Facsimile signatures and signatures transmitted via PDF will be treated as original signatures.

     

    25.        Headings in this Amendment are for reference only and do not affect the interpretation of this Amendment.

     

    [SIGNATURE PAGES FOLLOW]

     

    
      

      6

      
        

      
        Confidential

      

    

    IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their
        representatives thereunto duly authorized as of the Amendment Effective Date.

     

    

    	
            F. Hoffmann-La Roche Ltd

          	 
	 	 
	
            By:/s/James Sabry

          	 
	 	 	 
	
            Name:

          	
            James Sabry

          	 
	 	 	 
	
            Title:

          	
            Global Head, Pharma Partnering

          	 
	 	 	 
	
            By:/s/Barbara Schroeder de Castro Lopes

          	 
	 	 	 
	
            Name:

          	
            Barbara Schroeder de Castro Lopes

          	 
	 	 	 
	
            Title:

          	
            Authorized Signatory

          	 

    

    

    
      

      7

      
        

      
        Confidential

      

    

    

    IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their
        representatives thereunto duly authorized as of the Amendment Effective Date.

     

    

    	
            Hoffmann-La Roche Inc.

          	 
	 	 
	
            By: /s/ John Parise

          	 
	 	 	 
	
            Name:

          	
            John Parise

          	 
	 	 	 
	
            Title:

          	
            Authorized Signatory

          	 

    

    

    
      

      8

      
        

      
        Confidential

      

    

    

    IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their
        representatives thereunto duly authorized as of the Amendment Effective Date.

     

    

    	
            Ionis Pharmaceuticals, Inc.

          	 
	 	 
	
            By:/s/Brett P. Monia

          	 
	 	 	 
	
            Name:

          	
            Brett P. Monia

          	 
	 	 	 
	
            Title:

          	
            Chief Executive Officer

          	 

    

    

    
      

      9

      
        

      
        Confidential

      

    

    Press Release

     

    

    

    

    Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study

     

    

    	 	-	
            Positive data from a Phase 2 study of IONIS-FB-LRx support further development for treatment of patients with IgA nephropathy

          

    

    

    CARLSBAD, Calif., July 11, 2022 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing
        partner, Roche, will license and advance IONIS-FB-LRx, an investigational antisense medicine, into a Phase 3 clinical study in patients with immunoglobulin A nephropathy
        (IgAN). IgAN is a rare and serious condition that often leads to chronic kidney disease and renal failure. Roche’s decision to advance the program comes after positive data from a Phase 2 clinical study in which IONIS-FB-LRx met its primary endpoint of change in 24-hour urinary protein at 29 weeks compared to baseline.

    

    

    In the Phase 2 study, IONIS-FB-LRx (NCT04014335) demonstrated a favorable safety and tolerability profile. The study data are consistent with the clinical profile seen across Ionis’ other LICA programs,
          further validating how advancements in the company’s LIgand-Conjugated Antisense technology platform position Ionis to deliver potentially transformative treatments for a
          range of unmet medical needs. Data from the Phase 2 study of IONIS-FB-LRx in patients with IgAN has been
          submitted for presentation at an upcoming medical meeting.

    

    

    IgAN occurs when too much IgA protein accumulates in the kidneys, causing inflammation and tissue damage, which is the root cause of the disease. IONIS-FB-LRx was designed by Ionis to reduce the production of complement factor B (FB), which is associated with the development of several complement-mediated diseases, including
        IgAN.

    

    

    “Roche’s decision to advance the program reaffirms our shared confidence in the ability of Ionis’ antisense medicines to effectively target the root cause of difficult to treat diseases like immunoglobulin A
      nephropathy,” said Michael McCaleb, Ph.D., vice president, clinical development at Ionis. “The results of the Phase 2 study provide initial clinical evidence that IONIS-FB-LRx
      reduces complement and protein levels in the urine of patients with IgAN.”

    

    

    
      

      10

      
        

      
        Confidential

      

    

    Roche will lead and be responsible for the Phase 3 study of IONIS-FB-LRx in patients with IgAN and for future global development,
      regulatory and commercialization activities.

     

    IONIS-FB-LRx is also being evaluated in GOLDEN (NCT03815825), a Phase 2 clinical study to determine whether the medicine can slow or halt the progression of geographic atrophy due to age-related
          macular degeneration, or AMD. Ionis will receive $55 million from Roche for licensing IONIS-FB-LRx for IgAN
          and achieving a development milestone in the GOLDEN study.

     

    About IgA Nephropathy (IgAN)

    

    

    Immunoglobulin A nephropathy (IgAN) is an important cause of chronic kidney disease and renal failure. Also known as Berger’s disease, IgAN is characterized by deposition of IgA and Complement 3 (C3) activation
      products in the glomerular mesangium of the kidneys, resulting in inflammation and tissue damage. Although IgAN may occur at any age, it generally presents in the second or third decade of life. The clinical presentation, disease progression and
      histologic findings are highly variable among affected individuals. Current therapies are aimed at reduction of protein levels in the urine with administration of angiotensin inhibitors and control of blood pressure. Sometimes immunosuppressive
      therapies are given; however, this practice is not universally accepted.

    

    

    About Ionis Pharmaceuticals, Inc.

    

    

    For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a
      premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading,
      fully integrated biotechnology company.

    

    

    To learn more about Ionis, visit www.ionispharma.com and follow us on Twitter @ionispharma.

    

    

    Ionis' Forward-looking Statements

    

    

    This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, IONIS-FB-LRx and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk
      statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to, those related to our commercial products and the medicines in our
      pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis'
      forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.

    

    

    
      

      11

      
        

      
        Confidential

      

    

    Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on
      these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2021, and the most recent Form 10-Q quarterly filing, which are on
      file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

    

    

    In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

    

    

    Ionis Pharmaceuticals® is a trademark of Ionis Pharmaceuticals, Inc.

    

    

    Ionis Pharmaceuticals Investor Contact:

    760-603-2331

    

    

    Ionis Pharmaceuticals Media Contact:

    760-603-4679

    

    

    

    

    
      12Document

SEPARATION AGREEMENT AND FULL RELEASE

THIS SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”), dated as of June 7,
2022, is between Jeff Pedersen (referred to herein as “Employee”) and Angi Inc. (referred to herein as
“Employer”) (referred to collectively throughout as “parties”). The parties have agreed that Employee will separate Employee’s employment from Employer, as provided in this Agreement and, in connection with such separation of employment, Employer has agreed to provide Employee with certain benefits to which Employee would not otherwise be entitled absent Employee’s execution of this Agreement. In consideration of the mutual promises contained in this Agreement, Employee and Employer agree as follows:

1.Separation of Employment. The parties have agreed that Employee’s final day of employment with Employer is July 19, 2022 (the “Separation Date”). Employee will no longer serve as Employer’s Chief Financial Officer and will serve in a consultative capacity effective June 9, 2022. The parties further agree that, except as otherwise provided in this Agreement, all benefits and privileges of Employee terminate as of the close of business on the Separation Date.

2.Payments. In connection with Employee’s separation from employment, Company will pay Employee the gross sum of $500,000.00, and acceleration of Employee’s unvested equity that would vest within the 12 months of the date of Employee’s Separation Date; provided that any equity awards with a vesting schedule less frequent than annual shall be treated as though the vesting occurred in equal annual installments and any portion of any such awards that would have vested within 12 months of the Separation Date shall vest as of the Separation Date (the “Severance Payment”). For clarity, 479,094 RSUs will accelerate from Employee’s July 19, 2021 awards. The Severance Payment will be in the form of the cash severance and acceleration of Angi RSUs provided for in the two preceding sentences, and is expressly conditioned on the Employee having not revoked this Agreement pursuant to Paragraph 16 and having not revoked the Supplemental Release pursuant to Paragraph 6 herein. The Severance Payment shall be less required deductions, including deductions for applicable state and federal taxes. The Severance Payment is provided in exchange for the releases and other promises made by Employee herein as well as for the Supplemental Release to be delivered by Employee pursuant to Paragraph 18 below. The cash portion of the Severance Payment will be in the form of a company check and will be mailed within 30 calendar days following Employee’s execution and delivery of the Supplemental Release, as long as (1) Employee has delivered a signed copy of this Agreement and not revoked this Agreement pursuant to Paragraph 17, and (2) Employee has not revoked the Supplemental Release pursuant to Paragraph 6 therein. Employee acknowledges that Employee is not entitled to the Severance Payment outlined in this Section 2 and that Company has agreed to provide such benefit solely as consideration for Employee’s execution of this Agreement and the Supplemental Release. Employee further acknowledges that the Severance Payment is provided in full satisfaction of any and all obligations to Employee under the terms of the Employment Agreement between Employee and Company dated July 19, 2021 (the “Employment Agreement”).

3.Confidential Information, Non-Competition and Non-Solicitation. Employee agrees that as a result of Employee’s employment relationship with Employer, Employee has acquired access to or knowledge of confidential information and/or trade secrets, and that such information has economic value, either actual or potential, because such information is not generally known or readily ascertainable by proper means by others who can obtain economic value from its disclosure or use. Employee therefore understands and agrees that the Confidential Information, Non-Competition, Non-Solicitation and Proprietary Rights provision that Employee signed as part of Employee’s Employment Agreement shall remain in full force and effect following Employee’s termination of employment with Employer. Employee further agrees that as a result of Employee’s employment relationship with Employer, Employee has acquired access to sensitive customer information that is personal, confidential and may be subject to additional protection under contract, or local, state or federal statutes, rules, or regulations. Employee understands and acknowledges Employee’s obligation to keep such information confidential and agrees that Employee will not use or disclose to third parties any such confidential customer
			
	1

information. Employee understands that notwithstanding the foregoing, nothing in this Agreement prohibits Employee from reporting to any governmental authority information concerning possible violations of law or regulation and that Employee may disclose trade secret information to a government official or to an attorney and use it in certain court proceedings without fear of prosecution or liability provided Employee does so consistent with 18 U.S.C. 1833. This Agreement shall not limit any obligations Employee has under any employee confidentiality agreement, or terms and conditions of employment to which Employee has agreed, or applicable state law.

4.Return of Company Property. Employee acknowledges that prior to the date on which Employee signs this Agreement, Employee has returned all company property in Employee’s possession, including, but not limited to, any company credit card (or credit card on which the company is guarantor), computer, or printer. Employee is entitled to retain her company laptop computer at no cost, once it has been wiped clean and processed by Company’s information security department. Further, Employee agrees to repay to Employer the amount of any permanent or temporary advances and balance owing on any credit cards of any monies due and owing Employer or for which Employer is a guarantor.

5.Confidentiality and Nondisparagement. An essential and material term of this Agreement shall be that Employee shall keep confidential Employee’s understanding of the nature and existence and terms of this Agreement, negotiations leading to its execution, the fact of its execution, and the conveyance of the consideration to Employee, as well as the fact of and substance of negotiations, discussions, correspondence and other related matters that preceded the execution of this Agreement (collectively “Information”) to the extent permitted by law. Except as expressly allowed under law, Employee agrees that Employee will not, directly or indirectly, in any way publish, reveal, disclose, or communicate to any government agency, person, or entity any of the Information, except Employee’s spouse, or Employee’s legal or tax advisors (who shall agree to be bound to Employee’s non-disclosure obligations before Employee communicates Information to them), without first obtaining the express written consent of Employer. If any Information is sought from Employee pursuant to a valid and binding court order, or if Employee or any representative of Employee is subpoenaed or called as a witness at any deposition or trial in any action, regardless of whether Employee and/or Employer are Parties to said action, in which data, correspondence, communications or other documentation relating to the Information is sought, then Employee shall immediately notify Employer or any successor thereto of the time and place of the proceeding to which Employee or Employee’s representative has been called to testify sufficiently in advance, in which case Employee’s subsequent provision of such testimony shall not be considered a material breach of this Agreement.

Employee agrees to make every reasonable effort to maintain and protect the reputation of Employer and its affiliates and that of their businesses, products, directors, officers, employees, and agents. Employee further agrees that Employee will not disparage Employer and its affiliates or their businesses, products, directors, officers, employees, and agents (or persons representing them in their official capacity) or engage in any activities that reasonably could be anticipated to harm their reputation, operations, or relationships with current or prospective customers, suppliers, residents, clients or employees.

6.Full General Release. In consideration of the covenants and agreements contained herein, and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employee, for
Employee and on behalf of Employee’s heirs, successors, and assigns hereby irrevocably and unconditionally releases, waives and discharges Employer and its parents, subsidiaries or otherwise affiliated corporations, partnerships or business enterprises, and each of their respective past and former officers, partners, members, employees, agents, insurers, representatives, counsel, shareholders, directors, successors and assigns,
(collectively “Released Parties”) from any and all causes of action, claims, charges, demands, losses, damages, wages, compensation, benefits, costs, attorney’s fees and liabilities of any kind, including claims for age discrimination (collectively “Claims”) that Employee may have or claim to have, in any way relating to or
arising out of Employee’s employment with Employer through the date of this Agreement, regardless of whether these Claims are known or unknown. This irrevocable and unconditional release includes, but is not limited to, a
			
	2

release from any such matters or claims which Employee or anyone else could have raised on Employee’s behalf arising out of or pursuant to Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. 2000e et seq.; the Americans with Disabilities Act, 42 U.S.C. 12101, et seq.; the Fair Labor Standards Act, 29 U.S.C. '' 201 et seq.; the Employee Retirement Income Security Act, 29 U.S.C. '' 1001, et seq.; New York Human Rights Law, N.Y. Stat., Executive Law, Art. 15, Vol. 14, §§ 290-301, et seq., Equal Pay Law, N.Y. Stat. Vol. 20, Labor Law, Art. 6, § 194-198-a, ,, New York Persons with Disabilities Law, N.Y. Stat., Art. 4-B, Civil Rights Law, Vol. 5, § 47, et seq., New York Equal Rights Law, N.Y. Stat., Vol. 5, Civil Rights, Art. 4, § 40-c –45, et seq., New York Civil Rights Law, N.Y. Stat., Vol. 5, Civil Rights, Art. 7, § 79-e and 79-I, et seq., New York City Human Rights Law,
N.Y.C. Admin. Code § 8, et seq., Section 125 of the N.Y Workers’ Compensation Law, N.Y. Workers’ Comp. Law § 125, New York Minimum Wage Act, N.Y. Lab. Law § 663, United States Constitution, any and all amendments to said statutes, or any other federal, state or local employment law, any state contract or tort law, including, but not limited to, claims for infliction of emotional distress, wrongful termination, breach of the covenant of good faith and fair dealing, promissory estoppel or breach of an express or implied promise,
misrepresentation or fraud, retaliation, defamation of character, claims for attorney’s fees, or claims for any rights to future employment and benefits with Employer. Employee further understands that this release extends to all claims that Employee has or may have, based on any theory, whether developed or undeveloped, arising from or related to Employee’s employment or the separation of Employee’s employment with Employer, or any other fact or matter occurring prior to Employee’s execution of this Agreement. The Release provision of this Agreement does not apply, however, to any vested rights Employee may have under the Employer’s 401(k) Plan. It is the intent of the parties that this Full General Release shall fully resolve any and all Claims of any nature whatsoever arising out of Employee’s employment with Employer, now or previously existing which Employee may have against the Released Parties, whether presently known or unknown.

7.No Charges Filed By Employee/Subsequent Proceedings Barred. Employee hereby warrants and represents that Employee has not filed or caused to be filed any charge or claim against any Released Party with any administrative agency, court of law, or other tribunal. Employee agrees not to pursue or bring before any federal, state or other governmental authority or court any claim, complaint, or charge against any of the Released Parties relating to any of the matters released hereby, and Employee further agrees that Employee is not entitled to any remedy or relief if Employee were to pursue any such claim, complaint or charge. Nothing in this Agreement is intended to interfere with Employee’s right to participate in the charge filing or investigative process with the Equal Employment Opportunity Commission or similar local, state, or federal agency. However, Employee covenants and agrees that should any administrative proceeding, charge, lawsuit, or action of any type against Employer be filed by Employee or on his behalf, Employee will not accept any monies therefrom. Employee covenants and agrees that if Employee or Employee’s assigns or successors hereafter commence, join in, or in any manner seek relief through any suit arising out of, based upon, or relating to the released Claims or in any manner assert against Employer any of the released Claims, Employee will indemnify and hold harmless Employer, and including and in addition to any other damages caused to Employer thereby, the payment of attorneys’ fees incurred by Employer in defending or otherwise responding to said suit or claim. Employee also agrees to indemnify, hold harmless, and defend Employer against any and all past or future claims made, if any, with respect to the released Claims.

In addition, Employee understands and agrees that the provisions of the Arbitration Agreement signed by Employee previously shall remain in full force and effect following Employee’s termination of employment with Employer.

8.Compensation and Benefits. Employee affirms that Employee has been paid and received all wages and other compensation, as defined by either federal or state law, to which Employee has been entitled, including but not limited to any and all compensation, reimbursements, bonuses, commissions, overtime, vacation time, paid time off, leave, deferred compensation, or any other form of remuneration to which Employee has been entitled as a result of Employee’s employment with Employer. Except as provided above, Employee has no claim to any compensation or benefits of any kind or any other benefit plan available to employees of Employer by virtue of their employment with Employer.
			
	3

9.Acceptance Period; Right to Rescind and/or Revoke. Employee has been informed that the terms of this Agreement shall be open for acceptance by Employee for a period of at least 21 days after the date set forth above, during which time Employee may consider whether or not to accept this Agreement and seek counsel to advise Employee regarding the same. Employee agrees that changes to this Agreement, whether material or immaterial, will not restart this acceptance period. Employee has the right to revoke this Agreement only insofar as it extends to potential claims under the Age Discrimination in Employment Act by informing Employer of Employee’s intent to revoke this Agreement within seven (7) calendar days following Employee’s execution of it. Employee understands and agrees that this Agreement shall not become effective or enforceable until this 7- day revocation period has expired. Any rescission by Employee must be in writing and hand-delivered to Employer or, if sent by mail, postmarked within the applicable time period, sent by certified mail, return receipt requested, and addressed to Chief Legal Officer, Angi Inc., 130 East Washington Street, Indianapolis, IN 46204. Employee agrees that if Employee exercises any right of rescission or revocation, Employer may at its option either nullify this Agreement in its entirety or keep it in effect as to all claims not rescinded or revoked in accordance with the rescission or revocation provisions of this Agreement. In the event Employer opts to nullify the entire Agreement, neither Employee nor Employer will have any rights or obligations whatsoever under this Agreement. Any rescission or revocation, however, does not affect Employee’s separation from employment effective as of the date set forth in Section 1.

10.No Admission. This Agreement is not an admission by the Employer that it has taken any improper actions with respect to Employee in violation of any federal, state, or local law or regulation.

11.No Adequate Remedy. Employee agrees that it is impossible to measure in money all of the damages which will accrue to Employer by reason of Employee’s breach of any of Employee’s obligations under this Agreement. Therefore, if Employer shall institute any action or proceeding to enforce the provisions hereof, Employee hereby waives the claim or defense that Employer has an adequate remedy at law, and Employee shall not raise in any such action or proceeding the claim or defense that Employer has an adequate remedy at law.

12.Cooperation of Employee. Employee covenants and agrees to cooperate fully with the Released Parties concerning any business or legal matter about which Employee had knowledge during Employee’s employment with Employer or any Released Party. Employer will reimburse Employee for reasonable expenses associated with travel, meals, lodging, or other out-of-pocket expenses related to or associated with Employee’s cooperation with the Released Parties concerning any business or legal matter about which Employee had knowledge during Employee’s employment with Employer or any Released Party.

13.Report. During Employee’s employment, Employee understood that if Employee was aware of activity within Company that would violate federal and/or state law, that were discriminatory, or may have violated any policy or procedures, Employee had a duty to report such issues. Employee represents that Employee has no knowledge of any existing violations or suspected violations of any state or federal law or any Company policy. In addition, Employee represents that Employee has notified an officer of Company of any violation of Company policies and procedures in which Employee has any reason to suspect may lead to future violations of law. To the extent Company requests further information after Employee’s last day of employment related to this paragraph, Employee agrees to make herself reasonably available with respect to any follow-up inquiries deemed necessary

14.Waiver of Jury Trial. The Parties desire to avoid the uncertainty of and the additional time and expense related to a jury trial of any disputes arising hereunder. The parties further hereby irrevocably waive the right to a trial by jury on any claim arising out of or in any way related to this Agreement. Employee and Company acknowledge and agree that this waiver of a jury trial is knowingly, freely, and voluntarily given, is desired by both of them, and is in the best interests of Employee and Company
			
	4

15.Enforceable Contract; No Assignment; Entire Agreement. This Agreement shall be governed by the laws of the State of Colorado. If any part of this Agreement is construed to be in violation of any law, such part shall be modified to achieve the objective of the parties to the fullest extent permitted and the balance of this Agreement shall remain in full force and effect. This Agreement is personal to Employee and may not be assigned by Employee. Employee agrees that this Agreement, the Advisory Agreement, and the Arbitration Agreement executed by Employee contain the entire agreement between the parties with respect to the subject matter hereof and there are no promises, undertakings or understandings outside of this Agreement, except as specifically set forth herein and this Agreement supersedes all prior or contemporaneous discussions, negotiations and agreements, whether written or oral. Employee’s rights to payments or benefits from Employer are specified exclusively and completely in this Agreement. Any modification of or addition to this Agreement must be in writing, signed by an officer of Employer and Employee.

16.Older Workers Benefit Protection Act. In compliance with the Older Workers Benefit Protection Act, EMPLOYEE hereby acknowledges that:

a.he fully understands this Agreement;
b.this Agreement specifically applies to any rights or claims Employee may have against Company under the Federal Age Discrimination in Employment Act of 1967, as amended;
c.this Agreement does not purport to waive rights or claims that may arise from acts or events occurring after the date that this Agreement is executed by the parties;
d.the consideration provided for in this Agreement and the provisions of this Paragraph are in addition to that to which Employee is already entitled;
e.Employee has been advised to consult with an attorney prior to signing this Agreement;
f.Employee has been given a period of at least twenty-one (21) days within which to consider whether to sign this Agreement;
g.Employee agrees that changes to the terms of this Agreement, whether material or immaterial, will not restart the twenty-one (21) day consideration period;
h.Employee has voluntarily signed this Agreement; and
i.This Agreement shall be revocable for the seven (7) day period following execution of this Agreement by Employee, provided Employee delivers written notice of such revocation via hand-delivery or mail to Shannon Shaw, Chief Legal Officer, at shannon.shaw@angi.com, within the seven (7) day period. Accordingly, this Agreement shall not become effective or enforceable until the eighth (8th) day after Employee executes this Agreement (“Effective Date”). If Employee signs this Agreement prior to the expiration of the twenty-one (21) day period set forth in subparagraph (f), Employee voluntarily acknowledges and agrees to waive the full amount of time provided within which to consider this Agreement.

17.Supplemental Release. Employee agrees that on the Separation Date, he will execute and deliver the Supplemental Release attached hereto as Exhibit A to the Company. Employee agrees and acknowledges that execution of the Supplemental Release is a material term to this Agreement and that he is not entitled to any portion of the Severance Payment if he does not execute the Supplemental Release

BY SIGNING THIS AGREEMENT, EMPLOYEE HAS WAIVED ALL CLAIMS AGAINST COMPANY (INCLUDING WITHOUT LIMITATION ITS PREDECESSORS, SUCCESSORS, PARENT, SUBSIDIARIES, AND/OR AFFILIATED CORPORATIONS, AND ITS EMPLOYEES OR OTHER AGENTS), INCLUDING ALL CLAIMS FOR LOST WAGES, BENEFITS, COMPENSATORY
DAMAGES, OR PAYMENT OF ATTORNEYS’ FEES. EMPLOYEE CERTIFIES THAT HE IS ENTERING INTO THIS AGREEMENT KNOWINGLY, VOLUNTARILY, AND AFTER HAVING THE OPPORTUNITY TO CONSULT WITH AN ATTORNEY AND AFTER REVIEW OF THIS DOCUMENT IN ITS ENTIRETY.

IN WITNESS WHEREOF, the parties have executed this Agreement by their signatures below.
			
	5

EMPLOYEE:    EMPLOYER:
ANGI INC.
a Delaware corporation

/s/ Jeffrey W. Pedersen
By: /s/ Shannon Shaw                     

Name:    Jeff Pedersen    Name: Shannon Shaw                    

Address: 32 Malysana Lane
New Rochell, NY 10805

Title:  Chief Legal Officer        

Date: 6/8/2022    
			
	6

Exhibit A
Supplemental Release

GENERAL RELEASE (this “Release”) is made 7/19/2022 by and between Jeff Pedersen (“Employee”), in favor of Angi Inc., a Delaware corporation (the “Company”).

WHEREAS, Employee’s last day of employment with the Company was July 19, 2022; and

WHEREAS, Employee and the Company have agreed to settle in full all claims that Employee, on Employee's own behalf and for Employee's heirs, executors, administrators, successors and assigns, has or may have against the Company or any other Releasees (as defined below).

NOW, THEREFORE, in consideration of: (1) the promises and covenants herein, and (2) the consideration duly exchanged in accordance with the separation agreement executed as of June 8, 2022 by and between Employee and the Company (the “Separation Agreement”), the parties hereto agree as follows:

1.Except for the rights, duties, obligations, promises, covenants, warranties, indemnities, conditions, limitations and exclusions, if any, set forth in this Release and in the Separation Agreement:

(a)Employee, for Employee and on behalf of Employee’s heirs, successors, and assigns hereby irrevocably and unconditionally releases, waives and discharges Employer and its parents, subsidiaries or otherwise affiliated corporations, partnerships or business enterprises, and each of their respective past and former officers, partners, members, employees, agents, insurers, representatives, counsel, shareholders, directors, successors and assigns, (collectively “Released Parties”)from any and all causes of action, claims, charges, demands, losses, damages, wages, compensation, benefits, costs, attorney’s fees and liabilities of any kind, including claims for age discrimination (collectively “Claims”) that
Employee may have or claim to have, in any way relating to or arising out of Employee’s employment with Company through the date of this Agreement, regardless of whether these Claims are known or unknown. This irrevocable and unconditional release includes, but is not limited to, a release from any such matters or claims which Employee or anyone else could have raised on Employee’s behalf arising out of or pursuant to Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. 2000e et seq.; the Americans with Disabilities Act, 42 U.S.C. 12101, et seq.; the Fair Labor Standards Act, 29 U.S.C. 201 et seq.; the Employee Retirement Income Security Act, 29 U.S.C. 1001, et seq.; New York Human Rights Law, N.Y. Stat., Executive Law, Art. 15, Vol. 14, §§ 290-301, et seq., New York Equal Pay Law, N.Y. Stat. Vol. 20, Labor Law, Art. 6, § 194-198-a, ,, New York Persons with Disabilities Law, N.Y. Stat., Art. 4-B, Civil Rights Law, Vol. 5, § 47, et seq., New York Equal Rights Law, N.Y. Stat., Vol. 5, Civil Rights, Art. 4, § 40-c –45, et seq., New York Civil Rights Law, N.Y. Stat., Vol. 5, Civil Rights, Art. 7, § 79-e and 79-I, et seq., New York City Human Rights Law, N.Y.C. Admin. Code § 8, et seq., Section 125 of the
N.Y Workers’ Compensation Law, N.Y. Workers’ Comp. Law § 125, New York Minimum Wage Act,
N.Y. Lab. Law § 663, the United States Constitution, any and all amendments to said statutes; or any other federal, state or local employment law, any state contract or tort law, including, but not limited to, claims for infliction of emotional distress, wrongful termination, breach of contract (including claims for breach of Employee’s Employment Agreement), breach of the covenant of good faith and fair dealing, promissory estoppel or breach of an express or implied promise, misrepresentation or fraud, retaliation, defamation of character, claims for attorney’s fees, or claims for any rights to future employment and benefits with Company. Employee further understands that this release extends to all claims that Employee has or may have, based on any theory, whether developed or undeveloped, arising from or
related to Employee’s employment or the separation of Employee’s employment with Company, or any other fact or matter occurring prior to Employee’s execution of this Agreement. The Release provision of this Agreement does not apply, however, to any vested rights Employee may have under the Company’s 401(k) Plan. It is the intent of the parties that this Full General Release shall fully resolve any and all
			
	7

Claims of any nature whatsoever arising out of Employee’s employment with Company, now or previously existing which Employee may have against the Released Parties, whether presently known or unknown.

(a)Employee acknowledges and agrees that by virtue of the foregoing, Employee has waived any relief available to Employee (including without limitation, monetary damages, equitable relief and reinstatement) under any of the claims and/or causes of action waived in this Release. Therefore, Employee agrees that Employee will not seek or accept any award or settlement from any source or proceeding (including but not limited to any proceeding brought by any other person or by any government agency) with respect to any claim or right waived in this Release. Notwithstanding anything to the contrary set forth in this Release, Employee does not release, waive or discharge the Company from: (i) any claims to seek to enforce this Release or the Separation Agreement or (ii) any claims for indemnification or contribution under the Company’s organization documents, under any Company insurance policies, or under any federal or state laws with respect to any liability incurred by Employee as a director or officer of the Company.

(b)For the purpose of implementing a full and complete release and discharge of the Releasees, Employee acknowledges that this Release is intended to include in its effect, without limitation, other than specified in the Separation Agreement, all claims or other matters herein that neither party knows or suspects to exist in Employee’s favor at the time of execution hereof, and that this Release contemplates the extinguishment of any and all such claims or other such matters. The Releasees who are not a party to this Release are third party beneficiaries of this Release and are entitled to enforce its provisions.

2.This Release is not intended, and shall not be construed, as an admission that any of the Releasees has violated any federal, state or local law (statutory or decisional), ordinance or regulation, breached any contract or committed any wrong whatsoever against Employee.

3.In case any provision of this Release shall for any reason be held to be invalid, illegal or unenforceable in any respect by any court or administrative body with competent jurisdiction, such invalidity, illegality or unenforceability shall not affect the remaining provisions hereof, which shall remain in full force and effect. Any provision(s) so determined to be invalid, illegal or unenforceable shall be reformed so that they are valid, legal and enforceable to the fullest extent permitted by law or, if such reformation is impossible, then this Release shall be construed as if such invalid, illegal or unenforceable provision(s) had never been contained herein; provided that, upon a finding by a court of competent jurisdiction that this Release or any portion thereof is illegal and/or unenforceable, Employee hereby agrees to execute and deliver a release in substantially the same form as this Release, modified to the extent necessary so as to make it legal and enforceable.

4.This Release and all matters or issues related hereto shall be governed by the laws of the Colorado applicable to contracts entered into and performed therein (without reference to its principles of conflicts of laws). Any lawsuit brought by either party in connection with this Agreement shall be brought in the state and federal courts of Colorado. The parties acknowledge that such courts have jurisdiction to interpret and enforce the provisions of this Agreement, and the parties consent to, and waive any and all objections that they may have as to personal jurisdiction and/or venue in such courts.

5.This Release and the Separation Agreement is binding upon, and shall inure to the benefit of, the parties and their respective heirs, executors, administrators, successors and assigns.

6.Employee represents and warrants that, in deciding to execute this Releases, Employee has carefully read this Release in its entirety; Employee has had at least twenty-one (21) days to consider its terms and effects and to ask any questions that he may have of anyone, and that Employee has executed this Release voluntarily and with full understanding of its terms and its effects on him, and that no fact, evidence,
			
	8

event or transaction currently unknown to you but which may later become known to you will affect in any way or manner the final and unconditional nature of this Release. Employee further acknowledge that (a) the release provided for herein is granted in exchange for the receipt of consideration that exceeds the amount to which Employee would otherwise be entitled to receive upon termination of his employment; (b) the waiver of rights by Employee under this Release is knowing and voluntary; (c) Employee has been advised by the Company in writing to consult with an attorney, tax and/or financial advisor of your choice before signing this Release and that the Company has not provided Employee with any legal, tax or financial advice in connection with the same; (d) Employee has had answered to his satisfaction any questions he have asked with regard to the meaning and significance of any terms or provisions of this Release; and (e) this Release includes a release by Employee of all known and unknown claims. In the event that Employee does not accept this Release as set forth above, the obligation of the Company to provide the payments and benefits in the Separation Agreement shall immediately become null and void. This Agreement shall be revocable for the seven (7) day period following execution of this Agreement by Employee, provided Employee delivers written notice of such revocation via hand-delivery or mail to Shannon Shaw, Chief Legal Officer, at shannon.shaw@angi.com, within the seven (7) day period. Accordingly, this Agreement shall not become effective or enforceable until the eighth (8th) day after Employee executes this Agreement (“Effective Date”). If Employee signs this Agreement prior to the expiration of the twenty-one (21) day period set forth in subparagraph (f), Employee voluntarily acknowledges and agrees to waive the full amount of time provided within which to consider this Agreement. In the event that Employee does not accept this Release as set forth above and/or revokes within the seven day period following execution, the obligation of the Company to provide the payments and benefits as set forth in the Separation Agreement shall immediately become null and void.

/s/ Jeff W. Pedersen             
Jeff Pedersen

Date:        7/19/2022          
			
	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]